EDU 15 - ASTRO/ILROG Joint Session: The Comeback of RT - Radiation Therapy is Back in the Frontline of Managing Hodgkin and Indolent Lymphomas
MODERATOR(S)
Joachim Yahalom, MD, FASTRO - Memorial Sloan Kettering Cancer Center
session DESCRIPTION
In the past decade, the role of radiation therapy in lymphomas has shifted significantly. While initially there appeared to be data supporting a decreased need for RT in the frontline settings for non-Hodgkin and Hodgkin lymphomas, recent data showing unforeseen toxicities from chemotherapy, as well as changing approaches to using radiation therapy in lymphomas have solidified that radiation therapy is more important than ever in the frontline setting.
learning objectives
- Describe short- and long-term toxicities of chemotherapies used to treat common lymphomas, including secondary malignancies.
- Discuss new studies on how to best use radiation therapy in the front line setting for Hodgkin lymphoma and indolent NHL.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
| CAMPEP Credits: | 1.00 |
| MDCB Credits: | 1.00 |
Presentations
-
08:00am - 08:02am PTSpeaker: Joachim Yahalom, MD, FASTRO - Memorial Sloan Kettering Cancer Center, New York
-
08:02am - 08:17am PTSpeaker: George Mikhaeel, MD, MBBS - Guy's and St. Thomas' NHS Foundation Trust, London
-
08:17am - 08:32am PTSpeaker: Brandon Imber, MD, MS - Memorial Sloan Kettering Cancer Center, New York
-
08:32am - 08:47am PTSpeaker: Joanna Yang, MD, MPH - Washington University in St Louis, St Louis
-
08:47am - 09:00am PTSpeaker: Joachim Yahalom, MD, FASTRO - Memorial Sloan Kettering Cancer Center, New York